PharmAla Advances MDXX Manufacturing and Drug Pipeline

Toronto, Ontario, Canada, August 21, 2026

U.S. Patent Covers Enantioselective MDXX Manufacturing

The newly granted U.S. Patent No. 12,679,817 covers processes for preparing individual enantiomers of 3,4-methylenedioxymethamphetamine (MDMA) and N-methyl-1,3-benzodioxolylbutanamine (MBDB). Because these molecules are chiral, they exist as two mirror-image forms known as enantiomers, which can have different pharmacological properties. PharmAla stated that conventional manufacturing generally produces a racemic mixture containing both forms, while separating individual enantiomers at commercial scale can be challenging from a cost and yield perspective. The patented processes are designed to enable the direct preparation of individual R- or S-enantiomers, potentially providing a more efficient manufacturing pathway. The company believes the technology could support future production of R-MDMA and its own ALA-002 formulation, adding a manufacturing-process layer to its existing composition-of-matter and formulation intellectual property. The development is particularly relevant to PharmAla’s stated focus on cGMP pharmaceutical manufacturing. The company has built what it describes as a North American cGMP MDMA value chain covering GMP active pharmaceutical ingredient (API) manufacturing and drug-product formulation. By combining manufacturing expertise with intellectual property covering specific chemical processes, PharmAla is seeking to strengthen its position across the development and production stages of MDXX-class medicines.

APA-01 Development Strategy Moves In-House

PharmAla has also decided to exercise its option to cancel the proposed licensing of APA-01 to Restora Neurosciences. Under the previously announced structure, Restora Neurosciences was intended to lead the clinical and regulatory development of APA-01 through a jointly owned special-purpose vehicle involving PharmAla, Aluvaris, and Diteba. Following developments in PharmAla’s broader business strategy, the company stated that it will retain full ownership of APA-01 and its associated intellectual property. The company plans to evaluate potential pathways for APA-01, including in-house development and co-development opportunities. PharmAla said its engagement with prospective partners demonstrated interest in APA-01 as a potential molecule for investigation across multiple clinical disorders. The company is therefore retaining flexibility over how the candidate may be advanced while continuing to evaluate opportunities within the MDXX therapeutic space.

Canaccord Genuity Supports Strategic Growth

As another major corporate development, PharmAla has appointed Canaccord Genuity LLC as its exclusive investment banking partner and financial advisor. Under the engagement, Canaccord Genuity may serve as exclusive placement agent, lead agent, or lead bookrunner for potential private placements or public offerings during the agreed financing period. The firm may also advise PharmAla on potential business combinations, mergers, joint ventures, strategic alliances, and purchases or sales of equity, debt, or assets. The engagement does not guarantee that financing or a strategic transaction will occur. The appointment follows PharmAla’s efforts to expand its intellectual property and commercialization platform. The company said the relationship will provide access to expertise across the Canadian and U.S. life sciences and capital markets while supporting evaluation of future financing and strategic alternatives. PharmAla continues to advance its broader research and development activities, including preclinical research into patented novel chemical entities based on MDXX-class molecules. The company said proof-of-concept research is ongoing with the University of Arkansas Medical School, supporting its longer-term objective of developing novel therapies while maintaining a strong focus on regulatory and manufacturing capabilities.

Source: PharmAla Biotech press relese